Dorocubicel: First Approval
Molecular Diagnosis & Therapy · 2026
DOI: 10.1007/s40291-025-00824-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, 2026. Verfasst von Arnold Lee. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Drug Approval. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Dorocubicel (Zemcelpro®) is a cell therapy that includes UM171-expanded CD34+ haematopoietic stem cells derived from umbilical cord blood. It is being developed by Cordex Biologics for the treatment of haematological malignancies and non-malignant haematological disorders. In patients with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation (HSCT), transplantation with dorocubicel has been shown to result in neutrophil and platelet engraftment, as well as rapid T cell reconstitution. This article summarizes the key milestones in the development of dorocubicel leading to this first approval for the treatment of adult patients with haematological malignancies who require an allogeneic HSCT following myeloablative conditioning, for whom no other type of suitable donor cells is available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.
ORCID-Profile: Arnold Lee
Zitieren
APA
Lee, A. (2026). Dorocubicel: First Approval. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-025-00824-3
Vancouver
Lee A. Dorocubicel: First Approval. Molecular Diagnosis & Therapy. 2026. doi:10.1007/s40291-025-00824-3
BibTeX
@article{Lee2026,
author = {Lee, Arnold},
title = {Dorocubicel: First Approval},
journal = {Molecular Diagnosis & Therapy},
year = {2026},
doi = {10.1007/s40291-025-00824-3}
}
EUVIMED